Tumour gene expression signature in primary melanoma predicts long-term outcomes: A prospective multicentre study
Nuno A. Fonseca,
Göran B Jönsson,
Mark R Middleton,
David J. Adams,
Posted 25 Feb 2020
bioRxiv DOI: 10.1101/2020.02.24.961771
Posted 25 Feb 2020
Purpose: Predicting outcomes after resection of primary melanoma remains crude, primarily based on tumour thickness. We explored gene expression signatures for their ability to better predict outcomes. Methods: Differential expression analysis of 194 primary melanomas resected from patients who either developed distant metastasis (n=89) or did not (n=105) was performed. We identified 121 metastasis-associated genes that were included in our prognostic signature, Cam\_121. Several machine learning classification models were trained using nested leave-one-out cross validation (LOOCV) to test the capacity of the signature to predict metastases, as well as regression models to predict survival. The prognostic accuracy was externally validated in two independent datasets. Results: Cam\_121 performed significantly better in predicting distant metastases than any of the models trained with the clinical covariates alone (pAccuracy=4.92x10-3), as well as those trained with two published prognostic signatures. Cam_121 expression score was strongly associated with progression-free survival (HR=1.7, p=3.44x10-6), overall survival (HR=1.73, p=7.71x10-6) and melanoma-specific survival (HR=1.59, p=0.02). Cam_121 expression score also negatively correlated with measures of immune cell infiltration (ρ=-0.73, p<2.2x10-16), with a higher score representing reduced tumour lymphocytic infiltration and a higher absolute 5-year risk of death in stage II melanoma. Conclusions: The Cam_121 primary melanoma gene expression signature outperformed currently available alternatives in predicting the risk of distant recurrence. The signature confirmed (using unbiased approaches) the central prognostic importance of immune cell infiltration in long-term patient outcomes and could be used to identify stage II melanoma patients at highest risk of metastases and poor survival who might benefit most from adjuvant therapies.
- Downloaded 252 times
- Download rankings, all-time:
- Site-wide: 59,863 out of 88,613
- In bioinformatics: 6,397 out of 8,383
- Year to date:
- Site-wide: 10,979 out of 88,613
- Since beginning of last month:
- Site-wide: 15,804 out of 88,613
Downloads over time
Distribution of downloads per paper, site-wide
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!